MedTrace Logo

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.

NCT03553108 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-10-01

No results posted yet for this study

Summary

This is a phase 1 open label, 4 treatment, 4 sequence and 4 period crossover study in subjects with solid tumours no longer responding to, or eligible for standard therapies, and for whom there are no additional standard therapies likely to benefit the subject.

Conditions

  • Malignant Solid Tumor

Interventions

DRUG

Olaparib Treatment A

Olaparib Tablet 25 mg

DRUG

Olaparib Treatment B

Olaparib Tablet 100 mg

DRUG

Olaparib Treatment C

Olaparib Tablet 150 mg

DRUG

Olaparib Treatment D

Olaparib Tablet 250 mg

Sponsors & Collaborators

Principal Investigators

  • Kevin Punie · Universitaire Aiekenhuizen Leuven

  • Luc Dirix · GZA Ziekenhuizen

  • Guy Jerusalem · Centre Hospitalier Universitaire de Liege

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-16
Primary Completion
2019-03-12
Completion
2020-07-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553108 on ClinicalTrials.gov